{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:07:43Z","timestamp":1743484063946,"version":"3.37.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40273-023-01277-4","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T11:01:17Z","timestamp":1685271677000},"page":"981-997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness Analysis of MammaPrint\u00ae to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-2877","authenticated-orcid":false,"given":"Marianne","family":"Luyendijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7713-1450","authenticated-orcid":false,"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-1803","authenticated-orcid":false,"given":"Sanne M.","family":"Buijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-824X","authenticated-orcid":false,"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-5203","authenticated-orcid":false,"given":"Carin A. Uyl-de","family":"Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-0531","authenticated-orcid":false,"given":"Hedwig M.","family":"Blommestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"1277_CR1","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.20.01382","volume":"38","author":"MJ Piccart","year":"2020","unstructured":"Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, et al. Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors. J Clin Oncol. 2020;38:4120\u20139. https:\/\/doi.org\/10.1200\/JCO.20.01382.","journal-title":"J Clin Oncol"},{"key":"1277_CR2","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdy537","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700\u201312. https:\/\/doi.org\/10.1093\/annonc\/mdy537.","journal-title":"Ann Oncol"},{"key":"1277_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.7326\/0003-4819-158-12-201306180-00002","volume":"158","author":"JH Hayes","year":"2013","unstructured":"Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013;158:853\u201360. https:\/\/doi.org\/10.7326\/0003-4819-158-12-201306180-00002.","journal-title":"Ann Intern Med"},{"key":"1277_CR4","first-page":"1","volume":"20","author":"Ontario Health (Quality)","year":"2020","unstructured":"Ontario Health (Quality). Gene expression profiling tests for early-stage invasive breast cancer: A health technology assessment. Ont Health Technol Assess Ser. 2020;20:1\u2013234.","journal-title":"Ont Health Technol Assess Ser"},{"key":"1277_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2020.07.002","volume":"137","author":"VP Ret\u00e8l","year":"2020","unstructured":"Ret\u00e8l VP, Byng D, Linn SC, J\u00f3\u017awiak K, Koffijberg H, Rutgers EJ, et al. Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. Eur J Cancer. 2020;137:193\u2013203. https:\/\/doi.org\/10.1016\/j.ejca.2020.07.002.","journal-title":"Eur J Cancer"},{"key":"1277_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.21.02019","volume":"40","author":"JM Lopes Cardozo","year":"2022","unstructured":"Lopes Cardozo JM, Drukker CA, Rutgers EJ, Schmidt MK, Glas AM, Witteveen A, et al. Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial. J Clin Oncol. 2022;40:1335\u201345. https:\/\/doi.org\/10.1200\/JCO.21.02019.","journal-title":"J Clin Oncol"},{"key":"1277_CR7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/jamaoncol.2017.1261","volume":"3","author":"LJ Esserman","year":"2017","unstructured":"Esserman LJ, Yau C, Thompson CK, Van\u2019t Veer LJ, Borowsky AD, Hoadley KA, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol. 2017;3:1503\u201310. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1261.","journal-title":"JAMA Oncol"},{"key":"1277_CR8","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"23","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Al\u00e9s-Mart\u00ednez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;23:2381\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1103507.","journal-title":"N Engl J Med"},{"key":"1277_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)71171-4.","journal-title":"Lancet Oncol"},{"key":"1277_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer\u201496-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272\u201382. https:\/\/doi.org\/10.1093\/jnci\/djk049.","journal-title":"J Natl Cancer Inst"},{"key":"1277_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/JOM.0b013e3182820515","volume":"55","author":"NL Kleinman","year":"2013","unstructured":"Kleinman NL, Rohrbacker NJ, Bushmakin AG, Whiteley J, Lynch WD, Shah SN. Direct and indirect costs of women diagnosed with menopause symptoms. J Occup Environ Med. 2013;55:465\u201370. https:\/\/doi.org\/10.1097\/JOM.0b013e3182820515.","journal-title":"J Occup Environ Med"},{"key":"1277_CR12","unstructured":"Federation of Medical Specialists. Dutch Breast Cancer Guidelines \u2013 Geneexpression profiling [in Dutch: Borstkanker - Genexpressie profielen]. https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/risicoprofilering\/genexpressie_profielen.html. Accessed 20 Jan 2023."},{"key":"1277_CR13","unstructured":"National Health Care Institute the Netherlands (ZIN). Standpunt MammaPrint\u00ae bij vrouwen met vroeg stadium borstkanker (herbeoordeling). 2018. https:\/\/www.zorginstituutnederland.nl\/publicaties\/standpunten\/2018\/09\/27\/standpunt-mammaprint-bij-vrouwen-met-vroeg-stadium-borstkanker-herbeoordeling. Accessed 20 Jan 2023."},{"key":"1277_CR14","unstructured":"Netherlands Comprehensive Cancer Organization (IKNL). 2022. Netherlands Cancer Registry: data available on request."},{"key":"1277_CR15","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer: version 2.2022 \u2013\u2013 December 20, 2021. https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines. Accessed 04 April 2022.","DOI":"10.6004\/jnccn.2022.202glup"},{"key":"1277_CR16","unstructured":"Federation of Medical Specialists. Dutch Breast Cancer Guidelines. 2020. https:\/\/www.oncoline.nl\/borstkanker. Accessed 4 Apr 2020."},{"key":"1277_CR17","unstructured":"National Health Care Institute the Netherlands (ZIN). Dutch Guidelines for Economic Evaluations in Healthcare. 2016. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg. Accessed 15 Oct 2021."},{"key":"1277_CR18","unstructured":"National Health Care Institute the Netherlands (ZIN). Cost-effectiveness in practice [In Dutch: Kosteneffectiviteit in de praktijk]. 2015. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2015\/06\/26\/kosteneffectiviteit-in-de-praktijk. Accessed 7 June 2022."},{"key":"1277_CR19","unstructured":"Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A et all. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). Oxford Centre for Evidence-Based Medicine. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed 2 Jan 2023."},{"key":"1277_CR20","unstructured":"Statistics Netherlands. Survival probability by gender and age. 2022. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/70701ned\/table. Accessed 3 Feb 2022."},{"key":"1277_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","volume":"377","author":"JH van de Velde","year":"2011","unstructured":"van de Velde JH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet Oncol. 2011;377:321\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(10)62312-4.","journal-title":"Lancet Oncol"},{"key":"1277_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","volume":"5","author":"IA N\u00e6ss","year":"2007","unstructured":"N\u00e6ss IA, Christiansen S, Romundstad P, Cannegieter S, Rosendaal FR, Hammerstr\u00f8m J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692\u20139. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02450.x.","journal-title":"J Thromb Haemost"},{"key":"1277_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1634\/theoncologist.2015-0349","volume":"21","author":"KC Kadakia","year":"2016","unstructured":"Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016;21:539\u201346. https:\/\/doi.org\/10.1634\/theoncologist.2015-0349.","journal-title":"Oncologist"},{"key":"1277_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10549-009-0724-3","volume":"122","author":"MP van Herk-Sukel","year":"2010","unstructured":"van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JWW, Herings R. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122:843\u201351. https:\/\/doi.org\/10.1007\/s10549-009-0724-3.","journal-title":"Breast Cancer Res Treat"},{"key":"1277_CR25","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s11136-007-9202-8","volume":"16","author":"M Lidgren","year":"2007","unstructured":"Lidgren M, Wilking N, J\u00f6nsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16:1073\u201381. https:\/\/doi.org\/10.1007\/s11136-007-9202-8.","journal-title":"Qual Life Res"},{"key":"1277_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"M Janssen","year":"2019","unstructured":"Janssen M, Szende A, Cabases J, Ramos-Go\u00f1i JM, Vilagut G, K\u00f6nig H-H. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20:205\u201316. https:\/\/doi.org\/10.1007\/s10198-018-0955-5.","journal-title":"Eur J Health Econ"},{"key":"1277_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21510","volume":"21","author":"T Snowsill","year":"2017","unstructured":"Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling IM, et al. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol Assess. 2017;21:1\u2013280. https:\/\/doi.org\/10.3310\/hta21510.","journal-title":"Health Technol Assess"},{"key":"1277_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40262-021-01077-z","volume":"61","author":"CL Braal","year":"2022","unstructured":"Braal CL, Jager A, Hoop EO-d, Westenberg JD, Lommen KM, de Bruijn P, et al. Therapeutic drug monitoring of endoxifen for tamoxifen precision dosing: feasible in patients with hormone-sensitive breast cancer. Clin Pharmacokinetics. 2022;61:527\u201337. https:\/\/doi.org\/10.1007\/s40262-021-01077-z.","journal-title":"Clin Pharmacokinetics."},{"key":"1277_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40261-021-01114-6","volume":"42","author":"CL Braal","year":"2022","unstructured":"Braal CL, Kleijburg A, Jager A, Koolen SL, Mathijssen RH, Corro Ramos I, et al. Therapeutic drug monitoring-guided adjuvant tamoxifen dosing in patients with early breast cancer: a cost-effectiveness analysis from the prospective TOTAM TRIAL. Clin Drug Investig. 2022;42:163\u201375. https:\/\/doi.org\/10.1007\/s40261-021-01114-6.","journal-title":"Clin Drug Investig"},{"key":"1277_CR30","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","volume":"18","author":"C Bouwmans","year":"2015","unstructured":"Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van RL. The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18:753\u20138. https:\/\/doi.org\/10.1016\/j.jval.2015.05.009.","journal-title":"Value Health."},{"key":"1277_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh MM, Vermeulen KM, Evers SM, De Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19:34\u201352. https:\/\/doi.org\/10.1016\/j.jval.2016.01.003.","journal-title":"Value Health."},{"key":"1277_CR32","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.ejca.2010.02.035","volume":"46","author":"VP Ret\u00e8l","year":"2010","unstructured":"Ret\u00e8l VP, Joore MA, Knauer M, Linn SC, Hauptmann M, van Harten WH. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer. 2010;46:1382\u201391. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.035.","journal-title":"Eur J Cancer"},{"key":"1277_CR33","unstructured":"National Health Care Institute the Netherlands (ZIN). Pharmacotherapeutic Compass [In Dutch: Farmacotherapeutisch Kompas]. https:\/\/www.farmacotherapeutischkompas.nl\/. Accessed 27 Aug 2021."},{"key":"1277_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","volume":"29","author":"PH van Baal","year":"2011","unstructured":"van Baal PH, Wong A, Slobbe LC, Polder JJ, Brouwer WB, de Wit GA. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics. 2011;29:175\u201387.","journal-title":"Pharmacoeconomics"},{"key":"1277_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, Van Voorn G, Al M, Feenstra T. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349\u201361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2.","journal-title":"Pharmacoeconomics"},{"key":"1277_CR36","unstructured":"Netherlands Comprehensive Cancer Organization (IKNL). Breast Cancer in the Netherlands: trends 1989-2020 based on data from the Netherlands Cancer Registry [in Dutch: Borstkanker in Nederland trends 1989-2020, gebaseerd op cijfers uit de Nederlandse Kankerregistratie]. https:\/\/iknl.nl\/getmedia\/fe459c3a-c561-40de-b740-fff15997f020\/IKNL-Folder-Borstkanker-2020.pdf. Accessed 4 Apr 2022."},{"key":"1277_CR37","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/14737140.2018.1520096","volume":"18","author":"R Condorelli","year":"2019","unstructured":"Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2019;18:1101\u201312. https:\/\/doi.org\/10.1080\/14737140.2018.1520096.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1277_CR38","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","volume":"30","author":"A Ferreira","year":"2019","unstructured":"Ferreira A, Di Meglio A, Pistilli B, Gbenou A, El-Mouhebb M, Dauchy S, et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol. 2019;30:1784\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdz298.","journal-title":"Ann Oncol"},{"key":"1277_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10549-019-05410-w","volume":"178","author":"JG Verbeek","year":"2019","unstructured":"Verbeek JG, Atema V, Mewes JC, van Leeuwen M, Oldenburg HS, van Beurden M, et al. Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms. Breast Cancer Res Treat. 2019;178:573\u201385. https:\/\/doi.org\/10.1007\/s10549-019-05410-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1277_CR40","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"key":"1277_CR41","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jval.2021.01.010","volume":"24","author":"J Walraven","year":"2021","unstructured":"Walraven J, Jacobs MS, Uyl-de Groot CA. Leveraging the similarities between cost-effectiveness analysis and value-based healthcare. Value Health. 2021;24:1038\u201344. https:\/\/doi.org\/10.1016\/j.jval.2021.01.010.","journal-title":"Value Health."},{"key":"1277_CR42","unstructured":"Statistics Netherlands. Labor participation. 2022. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/82309NED\/table?fromstatweb. Accessed 1 Feb 2022."},{"issue":"2","key":"1277_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, L\u00e1ng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1803164.","journal-title":"N Engl J Med"},{"key":"1277_CR44","unstructured":"Federation of Medical Specialists. Dutch Endometrial Cancer Guidelines. 2011.\nhttps:\/\/richtlijnendatabase.nl\/richtlijn\/endometriumcarcinoom\/epidemiologie_en_etiologie.html. Accessed 02 June\n2022."},{"key":"1277_CR45","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(02)09962-2.","journal-title":"Lancet"},{"key":"1277_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-015-0089-z","volume":"98","author":"FJ L\u00f6tters","year":"2016","unstructured":"L\u00f6tters FJ, van den Bergh JP, de Vries F, Rutten-van M\u00f6lken MP. Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int. 2016;98:235\u201343. https:\/\/doi.org\/10.1007\/s00223-015-0089-z.","journal-title":"Calcif Tissue Int"},{"key":"1277_CR47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/13696998.2017.1331912","volume":"20","author":"M Heisen","year":"2017","unstructured":"Heisen M, Treur MJ, Heemstra HE, Giesen EB, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. J Med Econ. 2017;20:813\u201324. https:\/\/doi.org\/10.1080\/13696998.2017.1331912.","journal-title":"J Med Econ"},{"key":"1277_CR48","doi-asserted-by":"publisher","first-page":"e0165539","DOI":"10.1371\/journal.pone.0165539","volume":"11","author":"M Pennington","year":"2016","unstructured":"Pennington M, Gentry-Maharaj A, Karpinskyj C, Miners A, Taylor J, Manchanda R, et al. Long-term secondary care costs of endometrial cancer: a prospective cohort study nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). PLoS ONE. 2016;11:e0165539. https:\/\/doi.org\/10.1371\/journal.pone.0165539.","journal-title":"PLoS ONE"},{"key":"1277_CR49","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12885-018-4158-3","volume":"18","author":"GT Vondeling","year":"2018","unstructured":"Vondeling GT, Menezes GL, Dvortsin EP, Jansman FGA, Konings IR, Postma MJ, et al. Burden of early, advanced and metastatic breast cancer in The Netherlands. BMC Cancer. 2018;18:262\u201373. https:\/\/doi.org\/10.1186\/s12885-018-4158-3.","journal-title":"BMC Cancer"},{"key":"1277_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00405-015-3495-y","volume":"273","author":"N van der Linden","year":"2016","unstructured":"van der Linden N, Buter J, Pescott CP, Lalisang RI, De Boer JP, de Graeff A, et al. Treatments and costs for recurrent and\/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. Eur Arch Otorhinolaryngol. 2016;273:455\u201364. https:\/\/doi.org\/10.1007\/s00405-015-3495-y.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1277_CR51","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3463","author":"E Noels","year":"2020","unstructured":"Noels E, Hollestein L, Luijkx K, Louwman M, de Groot C, Bos R, et al. Increasing costs of skin cancer due to increasing incidence and introduction of pharmaceuticals, 2007\u20132017. Acta Derm Venereol. 2020. https:\/\/doi.org\/10.2340\/00015555-3463.","journal-title":"Acta Derm Venereol"},{"key":"1277_CR52","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.jval.2018.09.183","volume":"21","author":"J Gout-Zwart","year":"2018","unstructured":"Gout-Zwart J, Vondeling G, Rozenbaum M, Beby A, Postma M. PCN393-The burden of informal care for breast cancer patients in the Netherlands. Value Health. 2018;21:S81.","journal-title":"Value Health."},{"key":"1277_CR53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jval.2017.09.015","volume":"21","author":"AJ Lloyd","year":"2018","unstructured":"Lloyd AJ, Dewilde S, Noble S, Reimer E, Lee AY. What impact does venous thromboembolism and bleeding have on cancer patients\u2019 quality of life? Value Health. 2018;21:449\u201355. https:\/\/doi.org\/10.1016\/j.jval.2017.09.015.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01277-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01277-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01277-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T13:44:32Z","timestamp":1688564672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01277-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01277-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2023,5,28]]},"assertion":[{"value":"25 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was acquired for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Luyendijk, S.M. Buijs, S. Siesling have no conflicts of interest to declare. A. Jager reports an unrestricted grant received from Agendia<sup>\u00ae<\/sup> (MammaPrint<sup>\u00ae<\/sup>) to set up a database with genomic data (obtained with MammaPrint<sup>\u00ae<\/sup>) with the objective to discover new prognostic molecular markers within early stage breast cancer patients. Note: no restrictions were imposed on the use of the grant paid to the institute. Dr Blommestein reports a fee for participation in an advisory board from Pfizer, paid to the institute. C.A. Uyl-de Groot reports grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Jansen-Cilag, Bayer, Amgen, Genzyme, Merck, Gilead, Novartis, AstraZeneca, Roche, all payments to the institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The TOTAM study, from which we used patient-level data, was approved by the Local Ethics Committee (Erasmus MC, Rotterdam; MEC 17-548) and was registered at the Dutch Trial Registry (NL6918).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients participating in the TOTAM study gave their written informed consent for the study and also to use their data for other (related) research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The model is available on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"HB, AJ, ML contributed to the development of the study design. HB, AJ, ML, SB contributed to the data collection and data analyses. All authors contributed to the critical revision of the manuscript. All authors read and agreed with the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}